Most Recent Articles by Marc Iskowitz
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
Executives attending Cannes Lions Health weigh in on the imbalance seen in the U.S. between branded and unbranded drug ads.
Healthcare agencies focus on freeing pharma brands from their collaboration cocoons to work with health tech companies, while squaring away access concerns.
Five executives from the industry's largest holding companies discuss their move away from the traditional network structure.
Pharma marketing has long been deemed slow to adapt. Last weekend's Lions Health festival offered a glimpse of healthcare as a first mover.
More Articles by Marc Iskowitz
- Biogen ends Tecfidera DTC campaign, citing prescriptions
- As immuno-oncology therapies evolve, so will the marketing
- GSK Consumer Healthcare to prioritize digital after agency review
- Five things for pharma marketers to know: Thursday, July 21, 2016
- Five things for pharma marketers to know: Tuesday, July 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- W2O names Gillespie chief strategy officer of medtech practice
- Five things for pharma marketers to know: Wednesday, July 27, 2016
- DigitasLBi's Carlos Ricque on Why Simple Ads Are the Hardest to Make
- Healthcare marketers: Don't forget about the baby boomers
- Hacking Healthcare: Will It Help the Patient?